Join Growin Stock Community!
Beta
Back to ABBV.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-breakdown-chart

ABBV Revenue by Segments

Revenue by SegmentsRevenue by Segments

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, AbbVie's Immunology segment generated $7.29B in revenue, marking the latest data point and contributing the largest share to the total. Oncology followed with $1.61B, Aesthetics with $0.9B, and Neuroscience with $2.88B, reflecting a diverse segment performance amid ongoing portfolio dynamics. From Q2'23 to Q1'26, the Immunology segment showed stable growth with quarterly revenues fluctuating between $5.37B and $9.01B, peaking in Q4'23 and Q4'25, underscoring its role as the dominant contributor to overall revenue. Oncology exhibited moderate expansion from $1.48B to $2.62B peaks, while Aesthetics remained volatile and lower at $0.56B to $2.01B, and Neuroscience displayed significant surges to $5.19B in Q4'25 driven by key product launches, highlighting a broader upward trend in neuroscience offsetting variability in aesthetics. Total segment revenues trended positively overall, with stacked bars revealing immunology and neuroscience as primary growth drivers in this quarterly breakdown.